Pluristem Wins Cell Therapy Patent Case in Europe; European Patent Office Confirms Validity of Amended Claims Print E-mail
Tuesday, 07 October 2014 10:23
HAIFA, Israel--Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, announced today that its European Patent No. EP2200622, titled, "ADHERENT CELLS FROM ADIPOSE OR PLACENTA TISSUES AND USE THEREOF IN THERAPY", was upheld by the European Patent Office in amended form, affirming its validity. Pluristem's patent went through Opposition Proceedings before the Opposition Division of the European Patent Office, as a result of a challenge from a cell therapy company.
Read more...
 
Healthcare Valuation Experts Tackle Advanced Concepts Print E-mail
Monday, 06 October 2014 16:06
Healthcare valuation and consulting experts seeking help in navigating the treacherous regulatory landscape of healthcare can’t afford to miss an in-depth symposium this December presented by the National Association of Certified Valuators and Analysts™ (NACVA®) and the Consultants’ Training Institute™ (CTI™).  The Advanced Healthcare Valuation and Consulting Symposium will be held December 12–13, 2014, in San Diego, CA at the Solamar Hotel.
Read more...
 
Newsmakers: PTC Therapeutics, Herbalife, Alliqua Inc, Ariad Pharmaceuticals, Alcobra Ltd Print E-mail
Monday, 06 October 2014 15:28
Global equity markets extended a rally on Monday that drew strength from a forecast-beating U.S. jobs report last week that bolstered confidence in the American economy and the Federal Reserve's monetary policy, but the dollar gave up some of its gains.
Read more...
 
CEL-SCI Enrolls 16 Patients in September in Its Phase III Immunotherapy Head and Neck Cancer Trial Print E-mail
Friday, 03 October 2014 13:27
Vienna, VA-- CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of September the Company enrolled 16 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection).
Read more...
 
Clinical Decision Support Tools Can Help Doctors Quickly and Accurately Diagnose Ebola and other Infectious Diseases Print E-mail
Friday, 03 October 2014 09:03
ROCHESTER, NY--Four years ago, the Institute of Medicine recommended the Department of Health and Human Services promote the use of clinical decision support tools to ensure doctors quickly and accurately detect and diagnose bioterrorism and infectious disease outbreaks.
Read more...
 
Marijuana Use Associated with Lower Death Rates In Patients with Traumatic Brain Injuries Print E-mail
Thursday, 02 October 2014 12:33
  LOS ANGELES - Surveying patients with traumatic brain injuries, a group of Los Angeles Biomedical Research Institute (LA BioMed) researchers reported today that they found those who tested positive for THC, the active ingredient in marijuana, were more likely to survive than those who tested negative for the illicit substance.
Read more...
 
Newsmakers: The Female Health, GeoVax Labs, Heat Biologics, Ariad Pharmaceuticals', Incyte Corp. Print E-mail
Thursday, 02 October 2014 12:20
US stocks fluctuated amid an unexpected decline in jobless claims, while European equities plunged and the euro rose on concern additional stimulus will fail to boost inflation and revive the economy. Crude sank below $90 for the first time in 17 months.
Read more...
 
Protea Biosciences and InSphero AG successful in Mass Spectrometry Imaging of 3D microtissues Print E-mail
Thursday, 02 October 2014 11:31
MORGANTOWN, W.V., and Schileren, Switzerland October 2, 2014 -- Protea Biosciences Group, Inc. (OTCQB:PRGB) and InSphero AG jointly announced today an update from their collaboration focused on mass spectrometry imaging of InSphero’s 3D InSight™ microtissues.
Read more...
 
CEL-SCI & U.S. NAVY ADMINISTER MULTIKINE TO FIRST VOLUNTEER PATIENT IN PHASE I CLINICAL TRIAL FOR TREATMENT OF ANAL WARTS IN HIV/HPV CO-INFECTED PATIENTS Print E-mail
Monday, 29 September 2014 12:11
Vienna, VA, September 29, 2014 -- CEL-SCI Corporation (NYSE MKT: CVM) today announced the first volunteer patient has been enrolled and administered Multikine* (Leukocyte Interleukin, Injection) in a Institutional Review Board approved Phase I Clinical Trial evaluating peri-anal wart immunotherapy in HIV/HPV co-infected men and women at the Naval Medical Center San Diego (NMCSD).
Read more...
 
Provectus Biopharmaceuticals’ PV-10 Clinical Data on Melanoma Now Available for European Society for Medical Oncology 2014 Congress Print E-mail
Wednesday, 24 September 2014 11:52
KNOXVILLE, Tenn.--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that the abstract entitled, "Subgroup efficacy in patients receiving intralesional rose bengal to all existing melanoma in phase II study PV-10-MM-02," to be presented at the European Society for Medical Oncology 2014 Congress, is now available at https://www.webges.com/cslide/library/esmo/browse/search/8ct#9faD03sJ.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 9 of 12

Newsletter